Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 13 OCTOBER 2026 ASX RELEASE AMPLIA PRESENTS AT CG DRUG AND DEVICE CONFERENCE 2026 Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), is pleased to release CEO and Managing Director Dr Chris Burns’ presentation to the Canaccord Genuity Drug and Device conference in Noosa, QLD. A copy of the presentation is attached. This ASX announcement was approved and authorised for release by the Managing Director of Amplia Therapeutics Company Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Investor Contact: Hannah Howlett, Titch Comms Hannah@titchcomms.com.au +61 450 648 064 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane® ) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year. A new trial, exploring the combination of narmafotinib with next-generation kRAS G12C inhibitor olomorasib in second-line NSCLC, is planned to start late 2026. 1 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF NARMAFOTINIB – PANCREATIC CANCER AND BEYOND O c t o b e r 2 0 2 6 This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 Jun 2026. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below. Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia’s most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation. Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance. Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia’s actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company’s good faith assumptions as to the financial market, regulatory and other relevant environments that will exist and affect Amplia’s business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based. Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data. Financial Information: This Presentation contains historical financial information based on the Company’s results for the 12 month period ending 30 Jun 2026 and management accounts to 30 Jun 2026. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding. Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement. Disclaimer 2 Amplia Therapeutics Improving treatment options for hard-to-treat cancers Listed biotech company (ASX:ATX; OTCQB:INNMF) developing narmafotinib: a FAK inhibitor that decreases fibrosis and reverses adaptive resistance limiting new and existing cancer therapies; currently in Phase 2 for first-line treatment of advanced pancreatic cancer. Potentially synergistic with kRAS inhibitors: collaboration with Lilly to explore combination of narmafotinib with kRAS G12C inhibitor for the treatment of metastatic non-small cell lung cancer. Parallel development paths underway: registrational trial in pancreatic cancer to start imminently; clinical trial collaborations used as an entry point for high value indications and partnerships. Combination benefit proven in clinical studies: complete responses in metastatic pancreatic cancer (ACCENT Trial) and favorable tolerability profile, when combined with chemotherapy. CONFIDENTIAL 3 Exciting data from ACCENT Trial Superior to chemo alone Phase 2b/3 registration enabling FDA Orphan drug & Fast track designation Lead program PRROSE Trial HGSOC patients | ANZGOG High FAK expression 1 in 5 don’t respond to chemo Emerging opportunity 80+ kRAS drugs in development Preclinical ATX models show narmafotinib can improve kRAS inhibitors The FAK Opportunity A large and unmet clinical need exists in cancers where FAK contributes to disease Pancreatic Cancer Ovarian Cancer kRAS Combinations US$2.5b market1 US$3.9b market2 US$32b lung cancer market3 US$19b CRC market4 1. 2025 7MM’s, Clarivate/ Nature Reviews Drug Discovery 25, 416-417 (2026); 2. 2025 7MM’s, Clarivate/ Nature Reviews Drug Discovery 25, 674-675 (2026); 3. Global markets, Fortune Business Insights 4 Narmafotinib plus standard-of-care chemotherapy Newly diagnosed patients Metastatic disease 64 patients at top dose narmafotinib Phase 1b/2a clinical trial in Australia and South Korea Narmafotinib Chemotherapy Taken orally in days preceding chemotherapy Three infusions every four weeks ACCENT Pancreatic Cancer Trial 5 7.8% Complete response rate Superior to chemo alone (~0.2%) 70% Disease control rate Chemo alone - 50% 11.1 Median overall survival Chemo alone - 8.5 mo month s No Extra Burden Safety & tolerability Over chemo alone ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / Abraxane in first-line advanced pancreatic cancer months 5 CR’s and 1 pCR from 64 pts 8% CR, 28% PR, 34% SD mPFS 7.7 mos v 5.5 mos (MPACT) Main narma TEAEs: nausea, vomiting, diarrhoea 6 Underway Final planning ACCENT registration pathway ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 Daily dosing at two dose levels • Gemcitabine + Abraxane combination • 12 patients - 2 cohorts • 3–4 Australian sites • Safety, tolerability, PK + efficacy • Biomarker endpoints Timeline • First patient dosing Oct 2026 • Safety and PK review complete Q1 27 Builds on ACCENT Mini data to compare the two daily dosing levels head-to-head to identify the optimal dose of narmafotinib ahead of the Phase 3 study • Following Project Optimus* principles Pivotal registrational study conducted with the dose selected from P2b Designed to support FDA submission for narmafotinib approval in pancreatic cancer A three-part registration pathway designed around FDA feedback • FDA meeting planned Q2 27 • Start 2H 27 Timeline * Project Optimus: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus Final planning 7 5 Combinations with kRAS inhibitors FAK inhibition offers significant benefit Clinical studies demonstrating good activity 80+ kRAS drugs now in clinical development • Biotech and Pharma • Across pancreatic cancer, NSCLC, colorectal cancer and others Resistance and tolerability significantly limits long term treatment kRAS mutations prevalent in cancer Significant cancer driver in multiple indications 9 The Opportunity Ahead Combinations critical to development strategy 10 Narmafotinib target processes leading to resistance Narmafotinib breaks down fibrosis surrounding the tumour, improves immune infitrate and blocks survival and resistance pathways in cancer cells kRAS inhibitor kills most cells Resistance Cancer cells in tumour Cancer cells regrow 11 Resistance Narmafotinib target processes leading to resistance Narmafotinib breaks down fibrosis surrounding the tumour, improves immune infitrate and blocks survival and resistance pathways in cancer cells kRAS inhibitor kills most cells Cancer cells in tumour Dead cancer cells Narmafotinib’s mechanism appears agnostic to tumour type or kRAS mutation and has been demonstrated with a variety of kRAS inhibitors Narmafotinib 12 Olomorasib (100 mg, BID) Previously treated KRAS G12C-mutant advanced or metastatic NSCLC Phase 1b/2b study • Dose escalation of narmafotinib with standard dose olomorasib (approx. 20 pts) • Randomised 2-dose comparison – following Project Optimus guidelines (approx. 40 pts.) • Australian and US sites Contractual • Amplia to sponsor and fund study out of existing funds • Lilly to supply olomorasib in-kind for use in the study • Resulting data to be shared between both parties • Non-exclusive Narmafotinib (200 mg, QD) Narmafotinib (400 mg, QD) Narmafotinib (600 mg, QD) Olomorasib (100 mg, BID) Narmafotinib (Dose 1, QD) Narmafotinib (Dose 2, QD) Olomorasib (100 mg, BID) vs. Phase 1b Phase 2b Lilly Collaboration CONFIDENTIAL Enhancing efficacy of next-generation G12C inhibitor 13 2026 2027 2028 Estimated Development Timeline 2029 ACCENT ACCENT-mini ACCENT-reg PRROSE Olomorasib combination FDA Meeting FDA Meeting safety data CONFIDENTIAL 14 Timing Milestone Q4 2026 FDA Meeting discussing development Q4 2026 First patient dosed ACCENT-mini Q4 2026 First patient dosed PRROSE Q4 2026 Ethics submission Lilly trial Q1 2027 ACCENT-mini key data available Q1 2027 First patient dosed Lilly trial Q2 2027 FDA meeting finalising registration trial H2 2027 Preliminary data - PRROSE and Lilly trials Forthcoming Catalysts 24 15 Rhiannon Jones PhD GAICD COO MBBS FRACP CMO Jason Lickliter BCom MA CA GIA(Cert) CFO Warwick Tong MB ChB MPP GAICD Director Chris Burns PhD GAICD FAHMS CEO and MD Brett Carter BSc MBA GAICD Director Robert Peach PhD Director Jane Bell AM LLB LLM (Lond) FAICD Chair BOARD Hamish George SENIOR MANAGEMENT Jonathan Barlow LLB BSc GDipBA GAICD Head of BD Board and Management World-class expertise 16 Amplia Therapeutics Limited ASX: ATX​ | OTCQB: INNMF info@ampliatx.com ampliatx.com Chris Burns CEO and MD chris@ampliatx.com​